Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
Dow
Medtronic
Baxter
Moodys
McKesson

Last Updated: December 7, 2019

DrugPatentWatch Database Preview

Litigation Details for Senju Pharmaceutical Co. Ltd. v. Apotex Inc. (D. Del. 2012)

See Plans and Pricing

« Back to Dashboard

Senju Pharmaceutical Co. Ltd. v. Apotex Inc. (D. Del. 2012)

Docket   Start Trial Date Filed 2012-02-10
Court District Court, D. Delaware Date Terminated 2013-10-02
Cause 35:271 Patent Infringement Assigned To Sue Lewis Robinson
Jury Demand None Referred To
Parties ALLERGAN INC.; APOTEX CORP.; APOTEX INC.; KYORIN PHARMACEUTICAL CO. LTD.; SENJU PHARMACEUTICAL CO. LTD.
Patents 4,551,456; 4,980,470; 5,880,283; 6,333,045
Attorneys Francis J. Murphy , Jr.; Jack B. Blumenfeld; Maryellen Noreika
Link to Docket External link to docket
Small Molecule Drugs cited in Senju Pharmaceutical Co. Ltd. v. Apotex Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Senju Pharmaceutical Co. Ltd. v. Apotex Inc. (D. Del. 2012)

Date Filed Document No. Description Snippet Link To Document
2012-02-10 1 expiration of either the ‘045 Patent or U.S. Patent 5,880,283 (the ‘283 patent). 35. The January 13, 2012… certificate, and United States Patent No. 5,880,283 (“the ‘283 Patent”) under 35 U.S.C. §271(€)(2). T…United States Patent No. 6,333,045 (“the ‘045 Patent”), the claims set forth on the ‘045 Patent reexamination…claim of the ‘045 Patent, the ‘045 Patent reexamination certificate, and the ‘283 Patent has a statutory… Allergan has listed the ‘045 Patent, the ‘283 patent and other patents in the “Approved Drug Products External link to document
2012-02-10 3 Date of Expiration of Patent: 08/20/2019 for 6,333,045 and 12/05/2015 for 5,880,283.Thirty Month Stay Deadline… Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) …2012 2 October 2013 1:12-cv-00159-SLR Patent None District Court, D. Delaware External link to document
2012-02-10 4 Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,333,045 B1; 5,880,283;. (dmp, ) (Entered…2012 2 October 2013 1:12-cv-00159-SLR Patent None District Court, D. Delaware External link to document
2013-02-06 44 licensees of U.S. Patent Nos. 6,333,045 ("the '045 patent") and 5,880,283 ("the '…infringes the '045 and '283 patents (collectively, "the patents-at-issue"). (/d.) …claims 1-3, 6, 8, and 9 of the '045 patent with the U.S. Patent and Trademark Office ("PTO"…claims of a patent are invalid for "fail[ing] to meet the conditions for patentability within the…of the '045 patent, which is publicly available through the PTO's Public Patent Application Information External link to document
2013-03-01 52 U.S. Patent No. 4,980,470 (“the ‘470 patent”) and U.S. Patent No. 4,551,456 (“the ‘456 patent”) and,…U.S. Patent No. 4,780,465 (“the ‘465 patent”) and/or U.S. Patent No. 5,284,776 (“the ‘776 patent”) and…States Patent No. 6,333,045 ("the ‘045 Patent"), the claims set forth on the ‘045 Patent reexamination…States Patent Nos. 6,333,045 (“the ‘045 patent”), including the claims set forth in the ‘045 patent reexamination…claim of the ‘045 Patent, the ‘045 Patent reexamination certificate, and the ‘283 Patent has a statutory External link to document
2013-10-02 84 Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,333,045 B1; 5,880,283;. (Attachments…2012 2 October 2013 1:12-cv-00159-SLR Patent None District Court, D. Delaware External link to document
2012-03-16 9 expiration of either the ‘045 Patent or U.S. Patent 5,880,283 (the ‘283 patent). ANSWER: Apotex admits…enforceability of U.S. Patent Nos. 6,333,045, (“the ‘045 patent”) and 5,880,283 (“the ‘283 patent”). …certificate, and United States Patent No. 5,880,283 ("the ‘283 Patent") under 35 U.S.C. §271(e…validly construed claim of U.S. Patent No. 5,880,283 (“the ‘283 patent”) either literally or under the… U.S. Patent No. 5,880,283) Upon information and belief, the claims of the ‘283 patent are invalid External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Moodys
Boehringer Ingelheim
Medtronic
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.